AFP and neoplasm: In conclusion, we here provided the proof-of-concept of a novel approach to study the variability of the response to TKIs, which stems from the heterogeneity of tumor biology and drug individual susceptibility, by developing a physic-mathematical model able to interpret in a small cohort of patients the kinetics of PIVKA-II and AFP, combined with digital imaging.